Trial Profile
Phase I-II Multicenter Study of Genasense (Bcl-2 Antisense Oligonucleotide) [oblimersen] in Patients With Advanced Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Oblimersen (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 04 Oct 2005 New trial record.